Image in cardiology

Trillium: a new treatment for severe tricuspid regurgitation



Trillium: nuevo tratamiento de la insuficiencia tricúspide grave

Ignacio Cruz-González, a,b,c Javier Martín-Moreiras, a,b,c and Sergio López-Tejeroa,b,c,*

- a Sección de Hemodinámica e Intervencionismo Estructural, Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca (CAUSA), Salamanca, Spain
- ^b Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
- ^c Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Spain

Received 22 November 2022: Accepted 13 December 2022








Figure 1.

Figure 2.

Figure 3.

An 82-year-old woman with a history of iatrogenic aortic dissection repaired with an aortic valved conduit (Labcor-23), and severe mitral regurgitation repaired with MitraClip (Abbott, United States) was admitted due to congestive heart failure. Transesophageal echocardiography showed torrential tricuspid regurgitation with suboptimal anatomy for percutaneous edge-to-edge repair (coaptation point displaced towards the apex, pseudoprolapse of the anterior leaflet, and a cleft on the posterior leaflet). The right ventricle showed mild dysfunction (tricuspid annular plane systolic excursion was 14 mm and shortening fraction was 43%). Computed tomography showed a short distance from the suprahepatic veins to the right atrium (3.8 mm), indicating that the patient was not a good candidate for other heterotopic valves. The decision was made to implant Trillium (Innoventric, Israel) (figure 1), under compassionate use.

The 24-Fr delivery system was advanced over an extra-stiff wire (Lunderquist, Cook-Medical, United States) and the prosthesis was deployed from the superior to inferior cava veins. The 3 valves of the prosthesis were guided toward the tricuspid valve using radiopaque markers. The prosthesis was successfully implanted without complications (figure 2 and figure 3) (video 1 of the supplementary data), with a significant decrease in v-wave pressure in both cava veins.

Trillium is a new heterotopic bicaval prosthesis composed of a bare metal stent with radiopaque markers (blue-arrow) for precise deployment under fluoroscopy guidance. The main differences with other heterotopic devices are: it has 3 lateral valves (each of them can be potentially crossed, ie, with a pacemaker lead without interference on the function of the other 2) and a sealing skirt (red-arrow) that prevents any potential leak without obstruction of the suprahepatic veins (one of the main anatomical limitation of the other heterotopic valves). To the best of our knowledge, this is the first case reported of the use of this new prosthesis.

INFORMED CONSENT

The patient's consent was obtained for this publication.

FUNDING

This paper was not supported by any funding or other sources.

AUTHORS' CONTRIBUTIONS

S. López-Tejero and J. Martín-Moreiras reviewed the literatura on the topic and drafted the manuscript. I. Cruz-González led the research and supervised manuscript drafting and revised the final versión.

CONFLICTS OF INTEREST

The authors have no conflict of interest in relation to this paper.

APPENDIX. SUPPLEMENTARY DATA

Supplementary data associated with this article can be found in the online version, at https://doi.org/10.1016/j.rec.2022.12.008

^{*} Corresponding author.

E-mail address: ser_slt@hotmail.com (S. López-Tejero).

@serlotes @icruzgonzalez @jmmoreiras

Available online 29 December 2022